Tin tức & Cập nhật
Xem bài viết Ung thư
Xem

Mood, anxiety disorders may prolong hospital stay following radical cystectomy
For bladder cancer patients scheduled to undergo radical cystectomy, the presence of mood and/or anxiety disorders may lead to a longer length of hospital stay and increase the likelihood of discharge to a nonhome facility, a study reports.

Cetuximab plus chemoradiotherapy feasible in women with cervical carcinoma
Treatment with cetuximab plus cisplatin 30 mg/m2 and radiotherapy appears safe and well tolerated in women with cervical carcinoma, a study has shown. In addition, fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) has exhibited early evidence of response to neoadjuvant cetuximab.

Upfront ASCT + RVd improves PFS in NDMM
Upfront autologous stem cell transplantation (ASCT) plus lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), results of the phase III DETERMINATION trial showed.

Nonoperative management safe, feasible after complete response in rectal cancer
Patients with locally advanced rectal cancer who achieve complete response (CR) following sequential short-course radiation therapy (SCRT) and chemotherapy appear to benefit from nonoperative management (NOM) with a watch-and-wait strategy, which presents evidence for good anorectal functions, results of a study have shown.

Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD
Olaparib demonstrates clinical activity across patients with platinum-sensitive relapsed ovarian cancer and known BRCA mutation and homologous recombination deficiency (HRD), as shown in the phase II LIGHT study.

Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population
Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.



